Clopidogrel indications and usage: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
====1.1 Acute Coronary Syndrome (ACS)==== | ====1.1 Acute Coronary Syndrome (ACS)==== | ||
For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction ( | For patients with non-ST-segment elevation ACS [[[unstable angina]] (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, [[myocardial infarction]] (MI), or [[stroke]] as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. | ||
For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown. | For patients with [[ST-elevation myocardial infarction]] (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary [[percutaneous coronary intervention]] is unknown. | ||
The optimal duration of Plavix therapy in ACS is unknown. | The optimal duration of Plavix therapy in ACS is unknown. | ||
| Line 14: | Line 14: | ||
====1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease==== | ====1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease==== | ||
For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB/SANOFI PHARMACEUTICALS PARTNERSHIP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b | publisher = | date = | accessdate = }}</ref> | For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new [[ischemic stroke]] (fatal or not), new MI (fatal or not), and other vascular death.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB/SANOFI PHARMACEUTICALS PARTNERSHIP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 07:56, 7 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Indications and Usage
1.1 Acute Coronary Syndrome (ACS)
For patients with non-ST-segment elevation ACS [[[unstable angina]] (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.
The optimal duration of Plavix therapy in ACS is unknown.
1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.[1]
References
Adapted from the FDA Package Insert.